Wide Ranks

ATNFW

180 Life Sciences Corp.

0.0084

Top Statistics
Market Cap 0.0000 Forward PE 0.0000 Revenue Growth 0.00 %
Current Ratio 0.58 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 1 M Total Cash Per Share 1.18 Total Debt 442285
Total Debt To Equity Current Ratio 0.58 Book Value Per Share -0.2390
All Measures
Message Board Id finmb_587644367 Return On Equity -3.99 City Palo Alto
Uuid 8d0202a9-233b-3e2e-9b1f-a60d22bb781c Previous Close 0.0105 Book Value -0.2390
Beta 0.2470 Total Debt 442285 Volume 29675
Fifty Two Week Low 0.0077 Total Cash Per Share 1.18 Max Age 86400
Sand P52 Week Change 0.3133 Net Income To Common -12550828 Trailing Peg Ratio None
Total Cash 1 M Trailing PE 0.0000 Regular Market Previous Close 0.0105
Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000 Open 0.0077
Free Cashflow -4449469 State CA Dividend Yield 0.00 %
Return On Assets -0.6350 Time Zone Short Name EST Day Low 0.0077
Address1 Building 4 Target High Price 0.0000 Price Hint 4
Website https://180lifesciences.com Forward Eps 0.0000 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 28.80 % Is_sp_500 False
Regular Market Day High 0.0099 Profit Margins 0.00 % Fifty Two Week High 0.0099
Day High 0.0099 Regular Market Open 0.0077 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Operating Cashflow -4241737
Currency USD Time Zone Full Name America/New_York Is_nasdaq_100 False
Market Cap 0.0000 Zip 94306 Quote Type EQUITY
Industry Biotechnology Long Name 180 Life Sciences Corp. Regular Market Day Low 0.0077
Current Price 0.0084 Address2 Suite 200 3000 El Camino Real Financial Currency USD
Current Ratio 0.58 Industry Disp Biotechnology Country United States
Float Shares 838977 Forward PE 0.0000 Regular Market Volume 29675
Ebitda -8826971 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
180 Life Sciences Corp.

, a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases.

The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor.

The company is headquartered in Palo Alto, California.